D Orazio & Associates Inc. Purchases 33 Shares of Amgen Inc. (NASDAQ:AMGN)

D Orazio & Associates Inc. increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,101 shares of the medical research company’s stock after purchasing an additional 33 shares during the period. D Orazio & Associates Inc.’s holdings in Amgen were worth $969,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. United Community Bank bought a new stake in shares of Amgen during the fourth quarter valued at approximately $29,000. Horizon Financial Services LLC bought a new stake in Amgen in the first quarter valued at $28,000. nVerses Capital LLC bought a new stake in Amgen in the second quarter valued at $31,000. Bbjs Financial Advisors LLC bought a new stake in Amgen in the second quarter valued at $33,000. Finally, Western Pacific Wealth Management LP bought a new stake in Amgen in the fourth quarter valued at $37,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 0.3 %

AMGN stock opened at $329.98 on Thursday. The company has a market cap of $177.01 billion, a PE ratio of 47.14, a price-to-earnings-growth ratio of 2.85 and a beta of 0.61. The business has a 50-day simple moving average of $327.34 and a 200 day simple moving average of $303.13. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The firm’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the firm earned $5.00 EPS. Sell-side analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is presently 128.57%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. TD Cowen upped their price target on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Royal Bank of Canada increased their price objective on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $305.00 price objective (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Bank of America increased their price objective on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Eleven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $327.28.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.